344 related articles for article (PubMed ID: 27421908)
1. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
[TBL] [Abstract][Full Text] [Related]
2. [Recent Advances in α-dystroglycanopathy].
Kuga A; Kanagawa M; Toda T
Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
Manya H; Endo T
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
[TBL] [Abstract][Full Text] [Related]
4. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
Toda T
Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
[TBL] [Abstract][Full Text] [Related]
5. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
[TBL] [Abstract][Full Text] [Related]
6. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy.
Toda T; Kobayashi K; Takeda S; Sasaki J; Kurahashi H; Kano H; Tachikawa M; Wang F; Nagai Y; Taniguchi K; Taniguchi M; Sunada Y; Terashima T; Endo T; Matsumura K
Congenit Anom (Kyoto); 2003 Jun; 43(2):97-104. PubMed ID: 12893968
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation defects: a new mechanism for muscular dystrophy?
Grewal PK; Hewitt JE
Hum Mol Genet; 2003 Oct; 12 Spec No 2():R259-64. PubMed ID: 12925572
[TBL] [Abstract][Full Text] [Related]
8. The role of defective glycosylation in congenital muscular dystrophy.
Schachter H; Vajsar J; Zhang W
Glycoconj J; 2004; 20(5):291-300. PubMed ID: 15229394
[TBL] [Abstract][Full Text] [Related]
9. biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.
Gumlaw N; Sevigny LM; Zhao H; Luo Z; Bangari DS; Masterjohn E; Chen Y; McDonald B; Magnay M; Travaline T; Yoshida-Moriguchi T; Fan W; Reczek D; Stefano JE; Qiu H; Beil C; Lange C; Rao E; Lukason M; Barry E; Brondyk WH; Zhu Y; Cheng SH
Mol Ther; 2020 Feb; 28(2):664-676. PubMed ID: 31843448
[TBL] [Abstract][Full Text] [Related]
10. [Emerging novel therapeutic strategy for α-dystroglycanopathy by Large].
Saito F
Rinsho Shinkeigaku; 2011 Nov; 51(11):918-21. PubMed ID: 22277416
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycosylation of dystroglycan due to T192M mutation: a molecular insight behind the fact.
Bhattacharya S; Das A; Ghosh S; Dasgupta R; Bagchi A
Gene; 2014 Mar; 537(1):108-14. PubMed ID: 24361964
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
Kuwabara N; Manya H; Yamada T; Tateno H; Kanagawa M; Kobayashi K; Akasaka-Manya K; Hirose Y; Mizuno M; Ikeguchi M; Toda T; Hirabayashi J; Senda T; Endo T; Kato R
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9280-5. PubMed ID: 27493216
[TBL] [Abstract][Full Text] [Related]
13. [Congenital muscular dystrophy and alpha-dystroglycanopathy].
Saito F; Matsumura K; Hagiwara H; Shimizu T
Rinsho Shinkeigaku; 2008 Aug; 48(8):543-9. PubMed ID: 18939472
[TBL] [Abstract][Full Text] [Related]
14. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
15. A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients.
Humphrey EL; Lacey E; Le LT; Feng L; Sciandra F; Morris CR; Hewitt JE; Holt I; Brancaccio A; Barresi R; Sewry CA; Brown SC; Morris GE
Neuromuscul Disord; 2015 Jan; 25(1):32-42. PubMed ID: 25387694
[TBL] [Abstract][Full Text] [Related]
16. Zebrafish models for human FKRP muscular dystrophies.
Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
[TBL] [Abstract][Full Text] [Related]
17. [Dystroglycan linkage and muscular dystrophy].
Shimizu T
Rinsho Shinkeigaku; 2002 Nov; 42(11):1091-4. PubMed ID: 12784674
[TBL] [Abstract][Full Text] [Related]
18. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
[TBL] [Abstract][Full Text] [Related]
19. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
20. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
Kanagawa M; Toda T
J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
